Cancer therapeutics
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
34
NCT06552169
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
Phase: Phase 2
Role: Collaborator
Start: Jun 13, 2025
Completion: Jun 30, 2031
Loading map...